Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2021 Publisher: Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Calcort 6mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Round, white, uncoated tablets, marked with a cross on one face and a 6 on the other face. |
Active substance: Deflazacort 6mg.
Excipient(s) with known effect: Lactose monohydrate 153mg.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Deflazacort |
Deflazacort is a glucocorticoid. Its anti-inflammatory and immunosuppressive effects are used in treating a variety of diseases and are comparable to other anti-inflammatory steroids. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
Deflazacort is packed in blister packs of polyvinylchloride and aluminium foil presented in cardboard cartons. Each pack contains 60 tablets.
Aventis Pharma Limited, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
Trading as: Sanofi, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK
PL 04425/0629
Date of first authorisation: 28 April 1994
Date of latest renewal: 30 March 2005
| Drug | Countries | |
|---|---|---|
| CALCORT | Brazil, Germany, Estonia, Mexico, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
